DAV132, a novel, first-in-class, colon-targeted adsorbent capable of adsorbing a wide range of antibiotics, was well-tolerated in hospitalized elderly patients receiving oral/parenteral fluoroquinolones* (FQs), and protected the intestinal microbiota without influencing the plasma concentration of free FQs, the phase II European SHIELD trial has shown.
Individuals positive for COVID-19 who are asymptomatic carry similar viral loads as symptomatic patients, according to a study on a population in nursing homes presented during IDWeek 2020 — underscoring the importance of personal protective equipment (PPE) to limit viral transmission.
The long-acting injectable combining the INSTI* cabotegravir and the NNRTI** rilpivirine helped maintain virological suppression in HIV-positive individuals, according to the phase IIb POLAR study presented at ID Week 2020.
The investigational combination drug comprising the fourth-generation cephalosporin cefepime and the novel, potent extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (FPE) demonstrated superiority to the piperacillin-tazobactam (PTZ) regimen in patients with complicated* urinary tract infection/acute pyelonephritis (cUTI/AP) caused by ESBL-producing Enterobacterales, according to the results of the ALLIUM trial.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.
The oral prodrug tebipenem pivoxil hydrobromide (TBP-PI-HBr) was as effective as intravenous ertapenem in clearing infection and achieving clinical cure in adult patients hospitalized with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP), shows a head-to-head comparison study, ADAPT-PO.
Children with community-acquired pneumonia (CAP) who received a shorter course of antibiotic therapy were more likely to achieve a more desirable outcome than those on a standard-course regimen, according to the SCOUT-CAP* trial presented at ID Week 2020.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.
Wearing of face shields proves golden as a preventive measure, reducing not only the number of SARS-CoV-2 infections but also that of hospital-acquired infections among healthcare personnel, as shown in a study reported at the 2020 virtual IDWeek meeting.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.